CryoLife’s Surgical Hemostat Now Available in Canada

 

September 23, 2008

September 23, 2008 – CryoLife Inc. announced yesterday that its Hemostase MPH, used to control bleeding in general, cardiac and vascular surgery, is now distributed in Canada through Sorin Group Canada Inc.

Hemostase MPH is developed using Microporous Polysaccharide Hemospheres technology (MPH), which produces a plant-based powder that reportedly rapidly dehydrates blood, and enhances clotting on contact. The Hemostase MPH product received Health Canada approval in 2002, CE Mark approval in 2003 and FDA pre-market approval in 2006.

Available in a convenient ready-to-use applicator, Hemostase MPH, unlike many hemostatic agents, does not require additional operating room preparation or special storage conditions. Pre-clinical studies have shown that Hemostase MPH does not promote infection and absorbs within 24-48 hours of application at the wound site, compared to other surgical hemostats that can take several weeks to fully break down.

When used as a complement to BioGlue surgical adhesive, Hemostase MPH provides surgeons with the ability to quickly and confidently control active bleeding during surgery, a CryoLife executive stated.

For more information: www.cryolife.com